ASCO 2017: Cabozantinib vs Everolimus in Advanced Renal Cell Carcinoma
In patients with advanced renal cell carcinoma, cabozantinib improved outcomes compared with everolimus regardless of nephrectomy status, according to the results of the phase III METEOR trial, presented by Nizar M. Tannir, MD, FACP, of The University of Texas MD Anderson Cancer Center, Houston, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4570). However, for both treatment arms, nephrectomy was associated with a longer median overall survival.
A total of 658 patients with clear cell renal cell carcinoma were randomized to treatment with either cabozantinib or everolimus. All patients had received treatment with at least one prior vascular endothelial growth factor receptor tyrosine kinase inhibitor. Eighty-five percent of patients had prior nephrectomy. The investigators noted that all baseline characteristics were less favorable for those without nephrectomy.
For patients who had prior nephrectomy, progression-free survival was longer with cabozantinib than everolimus (7.4 vs 3.9 months); the same was true for those who had not had prior nephrectomy. In addition, median overall survival was longer with cabozantinib than everolimus regardless of nephrectomy status (22.0 vs 17.2 months with nephrectomy; 16.3 vs 12.5 without nephrectomy).